Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by legend1on Sep 15, 2003 9:12am

429 Views

Post# 6417054

RE: news

I have been a longtime shareholder and I must admit, I have been getting a little skeptical these days without prostate news and that second PP. But today's news really excites me because it dispells and doubts I had about ONC. You don't go out and get a group of professionals of this calibre without having a product that they IS going to have a gigantic impact on the future of cancer treatments. Kudos the the management at ONC for bringing it all together!!! Cheers, Legend

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features